5 claim verifications about United States Food and Drug Administration United States Food and Drug Administration ×
“Under the Dietary Supplement Health and Education Act of 1994, the U.S. Food and Drug Administration is prohibited from reviewing dietary supplements for safety or efficacy before they are marketed.”
DSHEA does not require FDA premarket approval for most dietary supplements, and products need not be proven safe or effective before sale. However, the claim that FDA is "prohibited from reviewing" supplements before marketing overstates the law. DSHEA requires a 75-day premarket notification for New Dietary Ingredients, during which FDA receives and may review safety information. The accurate framing is that FDA lacks mandatory premarket approval authority — not that it is categorically barred from any premarket review.
“Dietary supplements containing undisclosed pharmaceutical drugs — including steroids, thyroid hormones, and amphetamine-like stimulants — have been sold to consumers for years with limited regulatory consequence due to insufficient FDA enforcement capacity.”
The claim is substantially accurate. Peer-reviewed research documents over 1,000 dietary supplements adulterated with undisclosed pharmaceuticals — including synthetic steroids and stimulants — sold from 2007 through 2021, with some products remaining on shelves years after FDA warnings. However, the specific inclusion of "thyroid hormones" as a central adulterant pattern is not well-supported by the evidence. Additionally, the enforcement gap stems primarily from DSHEA's statutory design (classifying supplements as foods), not purely from insufficient FDA capacity — a meaningful distinction the claim obscures.
“Collagen supplements in the United States are largely unregulated by the Food and Drug Administration due to the Dietary Supplement Health and Education Act of 1994.”
The claim is substantially accurate. DSHEA (1994) does exempt collagen supplements from FDA premarket approval and shifts the burden of proving unsafety to the FDA, which multiple peer-reviewed and medical sources confirm. However, "largely unregulated" overstates the situation: the FDA retains meaningful post-market authority including cGMP manufacturing standards, labeling enforcement, adulteration removal powers, and premarket safety review for new dietary ingredients. A more precise framing would be "largely exempt from premarket approval requirements" rather than "largely unregulated."
“The United States Food and Drug Administration has approved leucovorin as a broad treatment for autism.”
This claim is false. The FDA approved leucovorin in March 2026 only for cerebral folate deficiency (CFD), an ultra-rare genetic condition affecting roughly 1 in a million people — not for autism. Leucovorin remains investigational for autism, the American Academy of Pediatrics does not recommend its routine use for autistic children, and a key study supporting leucovorin's autism benefits was retracted in January 2026 due to data irregularities. No FDA-approved broad treatment for autism spectrum disorder exists.
“Bioidentical hormones are chemically identical in molecular structure to hormones naturally produced by the human body.”
The claim is true. The Endocrine Society and the National Academies of Sciences both explicitly define bioidentical hormones as compounds with the exact same chemical and molecular structure as hormones naturally produced by the human body. This is the established scientific definition of the term. While compounded bioidentical products may lack FDA verification of their molecular identity, the claim itself is an accurate definitional statement supported by authoritative medical sources.